ALK-Abelló A/S provided revenue guidance for the full year 2023. For the period, the company expected revenue to grow by 7% to 11% in local currencies, which equals 8% to 12% growth disregarding the 1-year mandatory rebate increase in Germany for all prescription drugs. This rebate increase is expected to lower revenue by around DKK 50 million.

The company expected all sales regions to deliver growth and tablets will remain key to growth. Tablet sales are predicted to increase by up to 15%. On this basis, the company expected operating profit to further improve to align guidance with long-term financial ambitions, the company has decided to guide on the EBIT margin and the EBIT margin is expected at 13% to 15%, up from 10% in 2022, a margin improvement range between 25% to 45%.